These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2905645)

  • 1. [The electrophysiological approach to tardive dyskinesias].
    Rondot P
    Encephale; 1988 Sep; 14 Spec No():183-9. PubMed ID: 2905645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Electrophysiological and pharmacological analysis of L-dopa-induced dyskinesia and tardive dyskinesia (author's transl)].
    Bathien N; Rondot P; Koutlidis RM
    J Physiol (Paris); 1981 Apr; 77(1):131-41. PubMed ID: 6112268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug therapies for tardive dyskinesia: Part 1.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2011 Jun; 49(6):13-6. PubMed ID: 21598866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tardive dyskinesia. Pathophysiological mechanisms and clinical trials.
    Gerlach J
    Encephale; 1988 Sep; 14 Spec No():227-32. PubMed ID: 2905651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical aspects of tardive dyskinesias induced by neuroleptics].
    Villeneuve A; Lajeunesse C
    Encephale; 1988 Sep; 14 Spec No():209-14. PubMed ID: 2905648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Senile dyskinesias and tardive dyskinesias].
    Brion S; Plas J; Chevalier JF; Dussaux P
    Encephale; 1988 Sep; 14 Spec No():215-9. PubMed ID: 2905649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tardive dyskinesia: a review and current treatment options.
    Najib J
    Am J Ther; 1999 Jan; 6(1):51-60. PubMed ID: 10423647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
    Jackson MJ; Smith LA; Al-Barghouthy G; Rose S; Jenner P
    Exp Neurol; 2007 Mar; 204(1):162-70. PubMed ID: 17113078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias.
    Stahl SM; Davis KL; Berger PA
    J Clin Psychopharmacol; 1982 Oct; 2(5):321-8. PubMed ID: 6127351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
    Carta M; Carlsson T; Kirik D; Björklund A
    Brain; 2007 Jul; 130(Pt 7):1819-33. PubMed ID: 17452372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathophysiology and therapy of L-Dopa-induced dyskinesia].
    Hadj Tahar A; Bézard E; Grondin R; Gross CE; Bédard PJ
    Rev Neurol (Paris); 2003 Dec; 159(12):1125-42. PubMed ID: 14978413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia.
    Morselli PL; Fournier V; Bossi L; Musch B
    Psychopharmacology Suppl; 1985; 2():128-36. PubMed ID: 2860656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neuroleptic-induced movement disorders: historical perspectives].
    Wolf MA; Yassa R; Llorca PM
    Encephale; 1993; 19(6):657-61. PubMed ID: 12404786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.